Showing 4101-4110 of 10412 results for "".
- DermTech Receives Health Canada Approval to Market PLA and Non-invasive Biopsy Kithttps://practicaldermatology.com/news/dermtech-receives-health-canada-approval-to-market-pla-and-non-invasive-biopsy-kit/2457937/DermTech, Inc's licensee, DermTech Canada Inc., has received approval to market DermTech’s Pigmented Lesions Assay (PLA) and non-invasive biopsy kit for the detection of melanoma in Canada. DermTech Canada will market and sell the PLA, and samples will be processed at DermTech’s c
- NYC PrideFest: Galderma Aesthetics to Participatehttps://practicaldermatology.com/news/nyc-pridefest-galderma-aesthetics-to-participate/2461249/Galderma is participating in New York City's official LGBTQIA+ Pride (NYC Pride) event. This month marks the official launch of Restylane's "XpresYourself" communications campaign, which gives a nod to Restylane's XpresHAn Technology™, a u
- Bio-Oil Celebrates Body Confidence Through Body Positivity Month Campaignhttps://practicaldermatology.com/news/bio-oil-celebrates-body-confidence-through-body-positivity-month-campaign/2461538/Bio-Oil is rolling out a month-long campaign in celebration of February's Body Positivity Month to encourage self-love, promote body confidence, and highlight the role that Bio-Oil plays in helping people to love their stretch marks due to pregnancy, to scars from surgical procedur
- FDA Approves Expanded Indication for Merck's Keytruda for Treatment of Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-expanded-indication-for-mercks-keytruda-for-treatment-of-advanced-melanoma/2458773/The FDA has approved an expanded indication for Merck’s Keytruda® (pembrolizumab), an anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. This approval marks the second FDA-approved indicat
- Xylyx Bio's Matrikynes Improves the Structure, Function, and Appearance of Skinhttps://practicaldermatology.com/news/xylyx-bios-matrikynes-improves-the-structure-function-and-appearance-of-skin/2461645/Xylyx Bio’s
- Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI-100https://practicaldermatology.com/news/aditxt-inc-successfully-completes-preclinical-toxicity-study-of-its-psoriasis-drug-candidate-adi-100/2461260/Aditxt, Inc.’s
- Olay Rolls Out The Olay Skin Advisor 2.0https://practicaldermatology.com/news/olay-rolls-out-the-olay-skin-advisor-20/2458270/Olay’s new
- Meet Sentient’s Newest Executives...https://practicaldermatology.com/news/meet-sentients-newest-executives/2462094/Brian Kirk is Sentient’s new Chief Marketing Officer (CMO), and Jennifer Redmond joins as Chief Revenue Officer (CRO). Mr. Kirk is charged with elevating Sentient's marketing investment to support Tixel by Sentient and Sentient Sculpt, while advancing the
- European Commission Approves LEO Pharma’s Adtralza (tralokinumab) for the Treatment of Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/european-commission-approves-leo-pharmas-adtralza-tralokinumab-for-the-treatment-of-moderate-to-severe-ad-in-adolescents/2461394/The European Commission (EC)e xtended the marketing authorization for LEO Pharma’s Adtralz (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. “Safety is a priority when s
- Business News: Solta IPO Put on Icehttps://practicaldermatology.com/news/business-news-solta-ipo-put-on-ice/2461239/Bausch Health Companies Inc. is suspending its plans for the Solta IPO due to challenging market conditions and other factors. Bausch Health stated that the interests of the Company's stakeholders are best served in the near-term by focusing on driving Solta's revenue, profits a